News Story #19223
AusAm Biotechnologies Receives Approval to Market Test for Kidney Disease AusAm Biotechnologies Inc has received the CE Mark of approval for the Microalbumin Plus™, which aids in the detection of microalbuminari
Read MorePosted by Clinical Lab Products | Dec 11, 2003 | Miscellaneous, Osteoporosis |
AusAm Biotechnologies Receives Approval to Market Test for Kidney Disease AusAm Biotechnologies Inc has received the CE Mark of approval for the Microalbumin Plus™, which aids in the detection of microalbuminari
Read MorePosted by Clinical Lab Products | Dec 4, 2003 | Miscellaneous |
By Nicholas Borgert Bio-Rad Laboratories has expanded its TOX/See Rapid Urine Drug Screen platform with new capabilities to detect tricyclic antidepressants (TCA) and Ecstasy (MDMA). The new tests have been added to a TOX/See test menu tha
Read MorePosted by Clinical Lab Products | Nov 1, 2003 | Infectious Diseases |
By Nicholas Borgert Public awareness about infectious diseases continues to be an issue while diagnostics providers move forward with tests aimed at new risks and a few well-established ones. Recent months have brought introduction of a rapid HIV
Read MorePosted by Clinical Lab Products | Oct 10, 2003 | Miscellaneous |
Wampole Laboratories Signs Agreement to Acquire Exclusive US Distribution Rights for HIV Test Wampole Laboratories, a division of Inverness Medical Inc, has entered into an agreement with Efoora Inc of Buffalo Grove, Ill, for exclusive US distribu
Read MorePosted by Clinical Lab Products | Oct 1, 2003 | Molecular Diagnostics |
by Nicholas Borgert
Read More